Rapid Micro Biosystems (RPID) Stock: Buy, Sell, or Hold?
RPID - Rapid Micro Biosystems, Inc. Class A Common Stock
$0.92
-0.11 (-10.58%)
▼
5d:
-17.03%
30d:
-38.6%
90d:
-46.45%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 06, 2026
Get Alerted When RPID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RPID is down 17.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RPID is down 17.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RPID is currently trading at $0.92, which is considered oversold relative to its 30-day fair value range of $1.05 to $1.48.
Technical Outlook: Technically, RPID is in a strong downtrend. The price is currently testing key support at $0.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.6% recently.
Market Sentiment: RPID scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.75 (+524.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RPID is in a strong downtrend. The price is currently testing key support at $0.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.6% recently.
Market Sentiment: RPID scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.75 (+524.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.05 -
$1.48
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.6%)
- BULLISH: Trading 524.3% below Wall St target ($5.75)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.05 -
$1.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.92
Resistance Level
$1.20
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.29
Wall Street Target
$5.75
(+524.3%)
Revenue Growth (YoY)
10.9%
Profit Margin
-145.6%
Share & Embed Analysis
Last updated: October 02, 2026 3:16 AM ET
Data refreshes hourly during market hours. Next update: 4:16 AM
Data refreshes hourly during market hours. Next update: 4:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 44 HOLD |
